Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Ultomiris Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The growth observed historically can be attributed to more accurate identification of rare autoimmune diseases, significant progress in monoclonal antibody engineering, broader access provided by biologics reimbursement structures, heightened clinician understanding of complement disorders, and the existing hospital infusion infrastructure.
The projected growth during the forecast period is due to increasing investments in developing drugs for rare diseases, a rising acceptance of subcutaneous formulations, the expansion of home-based infusion care, a growing emphasis on managing long-term diseases, and an increasing need for therapies that reduce treatment burden. Key trends for this period involve the increasing adoption of long-acting complement inhibitors, a rising preference for extended dosing intervals, the growing utilization of targeted autoimmune therapies, the expansion of rare disease treatment programs, and an enhanced focus on patient-centric infusion models.
Get A Free Sample Report With In-Depth Market Insights:
Ultomiris Market Demand Drivers Opening New Revenue Streams
The Ultomiris market is projected to grow due to the rising occurrence of autoimmune conditions. These disorders involve the immune system erroneously attacking and damaging the body’s healthy cells and tissues. The increasing incidence of autoimmune conditions is linked to environmental factors, such as exposure to pollutants and chemicals, as well as enhanced diagnostic capabilities leading to more identified and treated cases. Ultomiris provides treatment for autoimmune conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by blocking complement protein C5, thereby decreasing immune system attacks on the body. For example, data from February 2024 provided by Arthritis Australia, an Australia-based non-profit organization, estimates that in 2025, around 212,136 males and 362,137 females are forecast to have rheumatoid arthritis (RA), with these figures anticipated to increase to approximately 280,040 males and 479,828 females by 2040. Consequently, the growing prevalence of autoimmune conditions is a primary factor driving the expansion of the Ultomiris market.
Ultomiris Market Driver: Impact Of Rising Healthcare Expenditure On The Market Growth
Ultomiris Market Segmentation: How Does The Market Break Down By Category?
The ultomiris market covered in this report is segmented –
1) By Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
2) By Formulation: Intravenous Solution, Subcutaneous Formulation
3) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies
4) By End User: Adult Patients, Pediatric Patients
Ultomiris Market Trends Powering Strategic Industry Growth
A significant development in the ultomiris market is the attainment of drug approvals from regulatory bodies to broaden its therapeutic applications and market presence. The drug approval process involves regulatory authorities evaluating and sanctioning a new medication for sale and use, thereby guaranteeing its safety, effectiveness, and quality based on extensive clinical trial data. For example, in March 2024, AstraZeneca, a UK-based pharmaceutical company, secured Food and Drug Administration (FDA) approval for ULTOMIRIS (ravulizumab-cwvz) specifically for treating adults diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who test positive for the anti-aquaporin-4 (AQP4) antibody. This approval is particularly noteworthy as ULTOMIRIS stands as the first long-acting C5 complement inhibitor for NMOSD, having demonstrated a 98.6% reduction in relapse risk in clinical trials. ULTOMIRIS functions by inhibiting the complement system, thereby preventing immune attacks on the central nervous system. Despite its benefits, it does pose risks, including serious meningococcal infections, and commonly reported side effects such as headache and urinary tract infections.
Ultomiris Market Competitive Overview And Top Companies
Major companies operating in the ultomiris market are AstraZeneca Plc.
View The Full Ultomiris Market Report:
Ultomiris Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the ultomiris market in 2025. The regions covered in the ultomiris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
